Clinical Trials Logo

Clinical Trial Summary

Because of the lengthening of life expectancy, more and more people are concerned with the effects of aging on their mental faculties (e.g., memory decline) and with the possibility of getting Alzheimer's Disease (AD) or other forms of dementia. This increasing awareness of AD has already resulted in a growing demand for neuropsychological testing. AD's research also emphasizes the need for early screening to improve the prediction of the disease progression and the efficacy of any future therapy. Such a drive to screen for pre-dementia raises the challenging issue of frontline identification of individuals in the preclinical or early clinical stages of AD. Mild Cognitive Impairment (MCI) is typically considered to be the prodromal state of AD, and is therefore at the core of the drive for early screening. Moreover, Pre-MCI so called SCI (Subjective Cognitive Impairment) can precede AD for 15 years. However, many individuals diagnosed with MCI do not convert to AD, some remaining stable and others even reversing back to normal (with rates of reversion to normal varying from 4.5% to as high as 53%). This over-diagnosis bias, which has been largely overlooked, is at the core of the present project at the interface of human and life sciences. Here, we argue that an important source of overdiagnosis in the prodromal state of AD comes from negative aging stereotypes (e.g., the culturally shared beliefs that aging inescapably causes severe cognitive decline and diseases such as AD) that permeate neuropsychological screening. There is ample evidence in the laboratory that such stereotypes contribute to the differences observed in the healthy population between younger and older adults in explicit memory tasks. Additionally, three pilot (lab) studies specifically conducted for the present ANR project showed that the threat of being judged stereotypically undermines the controlled use of memory of healthy older adults and simultaneously intensifies their automatic response tendencies, resulting in impaired memory performance. The present proposal goes several steps further by examining for the first time whether aging stereotypes are powerful enough to implicitly permeate the clinical neuropsychological testing and thus inflate memory deficits in older adults judged "at risk" (based on either epidemiological criteria or memory complaints), resulting in false-positive detection of SCI and MCI. This provocative hypothesis will be tested while 1) using biomarkers of neurodegeneration to distinguish false-positives from true MCI, and 2) using biomarkers of stress to examine whether and how aging stereotypes can lead to acute physiological stress during neuropsychological testing. This innovative project has the potential to offer new recommendations to improve the diagnosis accuracy of prodromal state of AD, with positive consequences for older people's wellbeing.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03138018
Study type Interventional
Source Assistance Publique Hopitaux De Marseille
Contact Bernard MICHEL, PH
Phone 491744675
Email bmichel@ap-hm.fr
Status Recruiting
Phase N/A
Start date July 6, 2018
Completion date July 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT00934531 - Donepezil and the Risk of Falls in Seniors With Cognitive Impairment N/A
Withdrawn NCT05033912 - A Study of CST-2032 in Subjects With Cognitive Impairment Phase 1
Recruiting NCT02854033 - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Completed NCT01902004 - Brain Aging and Treatment Response in Geriatric Depression Phase 4
Completed NCT01212692 - Effects of Mental Stimulation in Patients With Mild Cognitive Impairment Phase 2
Recruiting NCT00544791 - The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment Phase 2
Withdrawn NCT04055532 - Biomarkers in Neurodegenerative Diseases
Terminated NCT02180529 - The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment N/A
Completed NCT05108922 - A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) Phase 3
Recruiting NCT05865340 - To Exam the Efficacy of Oral Health and Mediterranean Diet Interventions in Preventing Cognitive Decline Among Older Adults With Mild Cognitive Impairment N/A
Completed NCT02110043 - Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS N/A
Completed NCT01383161 - 18-Month Study of Memory Effects of Curcumin Phase 2
Completed NCT01299766 - Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment Phase 3
Withdrawn NCT05321498 - Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation Phase 2
Completed NCT04748666 - PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia N/A
Withdrawn NCT01891383 - Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel
Recruiting NCT03448055 - Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health N/A
Completed NCT01231971 - Alzheimer's Disease Neuroimaging Initiative 2
Completed NCT01044758 - Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI) Phase 2
Recruiting NCT05014893 - Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline N/A